Goodpasture’s Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis

Lapointe, Elvy; Moghaddam, Bahar; Barclay, Krista; Traboulsee, Anthony; Neufeld, Peter R.

doi:10.1017/cjn.2018.325

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, alemtuzumab is associated with delayed secondary autoimmunity [ 5 ]. According to the CARE–MS study, the delayed secondary autoimmunity mostly occurred in the form of autoimmune thyroid disease and then autoimmune thrombocytopenia.…”

Section: Discussionmentioning

confidence: 99%

A case of relapsing anti-GBM disease secondary to alemtuzumab therapy

Leibowitz,

Manickam,

Srivastava

et al. 2023

CEN Case Rep

View full text Add to dashboard Cite

We report the first case of relapsing anti-GBM disease secondary to alemtuzumab in a 24-year-old female with relapsing–remitting multiple sclerosis. Initial anti-GBM disease was detected 10 months after alemtuzumab was given and was diagnosed by demonstrating high anti-GBM antibody titers and with a confirmatory kidney biopsy. The patient presented with a rapidly progressive glomerulonephritis with no pulmonary involvement. After appropriate treatment, the patient went into remission with undetectable anti-GBM antibodies. However, 20 months later, the patient re-presented with relapsing anti-GBM disease. Despite aggressive treatment, the patient became dialysis-dependent.

show abstract

Section: Discussionmentioning

confidence: 99%

A case of relapsing anti-GBM disease secondary to alemtuzumab therapy

Leibowitz,

Manickam,

Srivastava

et al. 2023

CEN Case Rep

View full text Add to dashboard Cite

show abstract

“…One known rare adverse event following Alemtuzumab administration is Anti-GBM syndrome (0.4%). 1,2 We detected pulmonary ground glass opacities in the chest CT performed at our center (Figure 2). After daily plasma exchange and immunosuppressive therapy with iv steroids and cyclosporine, the clinical condition of the patient improved, and diarrhea, fever, and chills resolved.…”

Section: Alemtuzumab Induced Anti-glomerular Basement Syndrome In a Patient With Relapsing-remitting Multiple Sclerosismentioning

confidence: 95%

“…One known rare adverse event following Alemtuzumab administration is Anti-GBM syndrome (0.4%). 1,2 We detected pulmonary ground glass opacities in the chest CT performed at our center…”

Section: Alemtuzumab Induced Anti-glomerular Basement Syndrome In a Pmentioning

confidence: 99%